BLIN vs XBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

BLIN

48.5
AI Score
VS
XBIO Wins

XBIO

57.0
AI Score

Investment Advisor Scores

BLIN

49score
Recommendation
BUY

XBIO

57score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric BLIN XBIO Winner
Forward P/E 12.1507 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 2.0% 12.0% XBIO
Earnings Growth 12.5% 0.0% BLIN
Tradestie Score 48.5/100 57.0/100 XBIO
Profit Margin -8.6% -75.9% BLIN
Beta 1.00 1.00 Tie
AI Recommendation BUY HOLD BLIN

Relative Price Performance (Last 90 Days)

BLIN 1M: -14.9% · 3M: -40.4% XBIO 1M: -23.4% · 3M: -26.9%

Current Technical Phase

BLIN

Markdown
Sell / avoid

Price below a falling SMA50 (slope -15.5%), weak momentum, RSI 33

RSI (14): 33.4 · Price: $0.70

XBIO

Markdown
Sell / avoid

Price below a falling SMA50 (slope -7.9%), weak momentum, RSI 32

RSI (14): 32.3 · Price: $1.93

Fundamentals Snapshot

Metric BLIN XBIO
Market Cap — —
Forward P/E 5.9 -5.7
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin 0.7% 1.0%
Operating Margin -0.1% -1.5%
EPS -0.10 -1.15
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, XBIO is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.